Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 15,990 Shares of Align Technology, Inc. (NASDAQ:ALGN)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its position in Align Technology, Inc. (NASDAQ:ALGN - Free Report) by 7.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 190,446 shares of the medical equipment provider's stock after selling 15,990 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned 0.26% of Align Technology worth $43,768,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. bought a new stake in shares of Align Technology during the 4th quarter valued at about $52,000. Stephens Inc. AR raised its holdings in Align Technology by 5.2% in the 4th quarter. Stephens Inc. AR now owns 3,517 shares of the medical equipment provider's stock worth $733,000 after acquiring an additional 175 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of Align Technology during the fourth quarter valued at $1,812,000. Empowered Funds LLC boosted its holdings in shares of Align Technology by 32.4% during the 4th quarter. Empowered Funds LLC now owns 1,280 shares of the medical equipment provider's stock valued at $267,000 after acquiring an additional 313 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Align Technology by 2.7% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 7,271 shares of the medical equipment provider's stock worth $1,516,000 after purchasing an additional 192 shares during the period. Hedge funds and other institutional investors own 88.43% of the company's stock.

Align Technology Trading Down 2.5 %

NASDAQ:ALGN traded down $5.18 during midday trading on Wednesday, hitting $205.34. 660,984 shares of the company traded hands, compared to its average volume of 792,960. The firm has a market capitalization of $15.33 billion, a P/E ratio of 36.60, a P/E/G ratio of 4.79 and a beta of 1.67. The firm's fifty day moving average is $220.34 and its 200-day moving average is $225.35. Align Technology, Inc. has a 12-month low of $196.09 and a 12-month high of $335.40.

Align Technology (NASDAQ:ALGN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.96 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.43 by ($0.47). Align Technology had a net margin of 10.54% and a return on equity of 13.84%. On average, research analysts expect that Align Technology, Inc. will post 8.09 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on ALGN. Piper Sandler lowered their target price on Align Technology from $275.00 to $270.00 and set an "overweight" rating on the stock in a report on Thursday, February 6th. Stifel Nicolaus dropped their price objective on shares of Align Technology from $285.00 to $275.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. Jefferies Financial Group reduced their target price on shares of Align Technology from $285.00 to $260.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Evercore ISI lifted their price target on shares of Align Technology from $240.00 to $260.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Finally, Mizuho assumed coverage on shares of Align Technology in a research report on Wednesday, December 4th. They set an "outperform" rating and a $295.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Align Technology has an average rating of "Moderate Buy" and a consensus target price of $271.40.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.